295
Participants
Start Date
May 9, 2016
Primary Completion Date
January 29, 2020
Study Completion Date
January 29, 2020
Nivolumab
Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
Dasatinib
Relatlimab
Ipilimumab
BMS-986205
Specified dose on specified days
Local Institution, Salzburg
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Local Institution, Rozzano
Local Institution, Milan
Local Institution, Milan
University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore
Sidney Kimmel Comprehensive Cancer Center, Baltimore
Virginia Cancer Specialists, PC, Fairfax
Univ of NC Shool of Medicine, Chapel Hill
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Pamplona
Local Institution, Toulouse
Sarah Cannon Cancer Center, Nashville
The West Clinic, P.C. d/b/a West Cancer Center, Germantown
The Ohio State University, Columbus
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Ce, Ann Arbor
Karmanos Cancer Institute, Detroit
Washington University, The Center for Advanced Medicine, St Louis
University of Kansas Cancer Center, Westwood
Local Institution, Paris
Sammons Cancer Center (Uso), Dallas
Us Oncology, Tyler
Texas Oncology, P.A., Fort Worth
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Denver, Aurora
Huntsman Cancer Institute, Salt Lake City
Comprehensive Cancer Centers of Nevada, Las Vegas
University of Southern California (USC), Los Angeles
Cedars-Sinai Medical Center, Los Angeles
University of Californa, Los Angeles (UCLA), Los Angeles
City of Hope National Medical Center, Duarte
University of California San Diego, San Diego
Hoag Memorial Hospital Presbyterian, Newport Beach
Local Institution, Villejuif
Northwest Cancer Specialists, Portland
University of Washington-Seattle Cancer Care Alliance, Seattle
Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber/Harvard Cancer Center, Boston
Fox Chase Cancer Center, Philadelphia
Local Institution, Clayton
Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences, Hamilton
University Of Ottawa - The Ottawa Hospital Cancer centre, Ottawa
Local Institution, Edmonton
Local Institution, Lausanne
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY